Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 7,476–7,500 of 27,380 studies, newest first · page 300 of 1096.

July 2023 25

  1. 2023-07-26

    Lysosomal dysfunction in Down syndrome and Alzheimer mouse models is caused by v-ATPase inhibition by Tyr682-phosphorylated APP βCTF

    ✓ Peer-reviewed Down syndrome and Alzheimer's Science advances

    Key finding: Notably, lowering APP-βCTF Tyr 682 phosphorylation below normal constitutive levels boosts v-ATPase assembly and activity, suggesting that v-ATPase may also be modulated tonically by phospho-APP-βCTF. +1 more finding

  2. 2023-07-26

    Artificial intelligence for dementia-Applied models and digital health

    ✓ Peer-reviewed Digital health tools Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: Such approaches will benefit also from improvements in remote data measurement, whether cognitive (e.g., online), or naturalistic (e.g., watch-based accelerometry). +1 more finding

  3. 2023-07-25

    Vertical Graphene-Based Printed Electrochemical Biosensor for Simultaneous Detection of Four Alzheimer’s Disease Blood Biomarkers

    ✓ Peer-reviewed Cognitive tests and assessment Biosensors

    Key finding: The customized electrochemical micro-workstation incorporates four electro-chemical control chips, enabling the sensor to simultaneously analyze four biomarkers. +4 more findings

  4. 2023-07-25

    Trem2 Enhances Demyelination in the Csf1r+/- Mouse Model of Leukoencephalopathy

    ✓ Peer-reviewed TREM2 and immune genetics Biomedicines

    Key finding: These data suggest that TREM2 contributes to microglial dyshomeostasis in CRL.

  5. 2023-07-25

    Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic

    ✓ Peer-reviewed Biomarkers Translational psychiatry

    Key finding: While in the whole MCI group, only GFAP was associated with Aβ PET centiloid. +1 more finding

  6. 2023-07-25

    Cerebrospinal fluid biomarkers in the Longitudinal Early-onset Alzheimer's Disease Study

    ✓ Peer-reviewed Biomarkers Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: Biomarkers were correlated with one another. +4 more findings

  7. 2023-07-25

    Plasma biomarkers of neurodegeneration in mild cognitive impairment with Lewy bodies

    ✓ Peer-reviewed Biomarkers Psychological medicine

    Key finding: Probable MCI-LB had elevated GFAP (p < 0.001) and NfL (p = 0.012) relative to controls, but not significantly lower Aβ42/40 (p = 0.06). +4 more findings

  8. 2023-07-25

    Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update

    ✓ Peer-reviewed Treatments Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

    Key finding: The clinical effects of these agents are modest, however, and associated with amyloid-related imaging abnormalities (ARIA).

  9. 2023-07-24

    Caregiver burden related to feeding process in Alzheimer's disease

    ✓ Peer-reviewed Caregiving Dementia & neuropsychologia

    Key finding: We included 60 AD individuals-caregivers dyads. +4 more findings

  10. 2023-07-24

    The fructose survival hypothesis for obesity

    ✓ Peer-reviewed Risk factors Philosophical transactions of the Royal Society of London. Series B, Biological sciences

    Key finding: While this response is aimed to be modest and short-lived, the response in humans is exaggerated due to gain of 'thrifty genes' coupled with a western diet rich in foods that contain or generate fructose. +4 more findings

  11. 2023-07-24

    Current Diagnostic Pathways for Alzheimer's Disease: A Cross-Sectional Real-World Study Across Six Countries

    ✓ Peer-reviewed Health systems and care delivery Journal of Alzheimer's disease reports

    Key finding: Factors that influenced risk of not receiving a diagnosis were HCP type (higher for primary care physicians versus specialists) and region (highest in China and Germany).

  12. 2023-07-24

    Personalized Integrated Care Promoting Quality of Life for Older People: Protocol for a Multicenter Randomized Controlled Trial

    ✓ Peer-reviewed Treatments JMIR research protocols

    Key finding: The study protocol is part of a project approved and funded by the European Commission Horizon 2020 (grant agreement number 875221). +2 more findings

  13. 2023-07-24
  14. 2023-07-22

    Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease

    ✓ Peer-reviewed Biomarkers Journal of neurology

    Key finding: Plasma glial fibrillary acidic protein significantly correlated with cognitive function tests, including all subdomains, with a notable increase in the PDD group compared with the HC and PDND groups, while plasma neurofilament light chain captured both cognitive decline and disease severity in the PDND and PDD groups. +2 more findings

  15. 2023-07-22

    Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: observational analysis

    ✓ Peer-reviewed Disparities Alzheimer's research & therapy

    Key finding: These results highlight the need to increase the overall detection rates of MCI and of dementia particularly in socioeconomically disadvantaged groups. +3 more findings

  16. 2023-07-22
  17. 2023-07-21

    A universal neocortical mask for Centiloid quantification

    ✓ Peer-reviewed Brain scans and imaging Alzheimer's & dementia (Amsterdam, Netherlands)

    Key finding: In the GAAIN dataset, the universal mask led to a small reduction in the variance of the YC, and a small increase in the inter-tracer agreement. +4 more findings

  18. 2023-07-21

    Plasma neurofilament light in behavioural variant frontotemporal dementia compared to mood and psychotic disorders

    ✓ Peer-reviewed Biomarkers The Australian and New Zealand journal of psychiatry

    Key finding: Large differences were seen between bvFTD (mean NfL 34.9 pg/mL) and all PPDs and controls (all < 11 pg/mL). +4 more findings

  19. 2023-07-21

    The effects of COVID-19 on cognitive performance in a community-based cohort: a COVID symptom study biobank prospective cohort study

    ✓ Peer-reviewed Cognitive tests and assessment EClinicalMedicine

    Key finding: Stratification by self-reported recovery revealed that deficits were only detectable in SARS-CoV-2 positive individuals who did not feel recovered from COVID-19, whereas individuals who reported full recovery showed no deficits. +1 more finding

  20. 2023-07-21
  21. 2023-07-21

    Frontotemporal Dementia, Where Do We Stand? A Narrative Review

    ✓ Peer-reviewed Digital health tools International journal of molecular sciences

    Key finding: Here, we aim to provide a state of the art on the pathogenesis of this disease, starting with established findings and integrating them with more recent ones. +4 more findings

  22. 2023-07-19

    Proteomics analysis of plasma from middle-aged adults identifies protein markers of dementia risk in later life

    ✓ Peer-reviewed Disease mechanisms Science translational medicine

    Key finding: We found 32 dementia-associated plasma proteins that were involved in proteostasis, immunity, synaptic function, and extracellular matrix organization. +3 more findings

  23. 2023-07-18

    Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial

    ✓ Peer-reviewed Prevention and risk Lancet (London, England)

    Key finding: These findings suggest that a hearing intervention might reduce cognitive change over 3 years in populations of older adults at increased risk for cognitive decline but not in populations at decreased risk for cognitive decline. +4 more findings

  24. 2023-07-18

    Trial of the MIND Diet for Prevention of Cognitive Decline in Older Persons

    ✓ Peer-reviewed Prevention and risk New England Journal of Medicine

    Key finding: Among cognitively unimpaired participants with a family history of dementia, changes in cognition and brain MRI outcomes from baseline to year 3 did not differ significantly between those who followed the MIND diet and those who followed the control diet with mild caloric restriction. +4 more findings

  25. 2023-07-17

    Trial of Solanezumab in Preclinical Alzheimer's Disease

    ✓ Peer-reviewed Brain scans and imaging The New England journal of medicine

    Key finding: Solanezumab, which targets monomeric amyloid in persons with elevated brain amyloid levels, did not slow cognitive decline as compared with placebo over a period of 240 weeks in persons with preclinical Alzheimer's disease. +2 more findings

Browse the library by subject, with the full score breakdown →